AKT1 and obstructive sleep apnea syndrome: Crucially, silencing SQLE was proven to deactivate the FAK/PI3K/Akt/mTOR pathway, indicating that targeting SQLE protein has considerable therapeutic potential for high‐risk OSA patients.